Bioceltix (WAR:BCX) ROCE % : -30.83% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bioceltix ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bioceltix's annualized ROCE % for the quarter that ended in Sep. 2024 was -30.83%.

Bioceltix ROCE % Historical Data

The historical data trend for Bioceltix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioceltix ROCE % Chart

Bioceltix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-82.73

-87.34

-88.75

-152.82

-170.73

Bioceltix Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial													-87.67	-120.65	-196.39	-65.10	-30.83

Bioceltix ROCE % Calculation

Bioceltix's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-13.659	/	( ( (7.653 - 2.248)	+	(12.735 - 2.139) )	/ 2 )
	=	-13.659	/	( (5.405	+	10.596)	/ 2 )
	=	-13.659	/	8.0005
	=	-170.73 %

Bioceltix's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-13.368	/	( ( (52.007 - 6.98)	+	(44.392 - 2.688) )	/ 2 )
	=	-13.368	/	( ( 45.027	+	41.704 )	/ 2 )
	=	-13.368	/	43.3655
	=	-30.83 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Bioceltix (WAR:BCX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bioceltix ROCE % Related Terms

Thank you for viewing the detailed overview of Bioceltix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioceltix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioceltix SA (WAR:BCX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bierutowska 57-59 Street, Wroclaw, POL, 51-317

Website

https://www.bioceltix.com

Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.